Home › Research › Disease mechanisms
α-synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies
Francisco Javier Padilla-Godínez, Eunice Ruth Vázquez-García, María Isabel Trujillo-Villagrán, Luis Oskar Soto-Rojas, Marcela Palomero‐Rivero, Omar Hernández‐González, Francisco Pérez-Eugenio, Omar Collazo-Navarrete et al.. Frontiers in Neuroscience, 2025-03-27
Topic: Brain proteins, microglia and lab models
Plain-language summary
Neurodegenerative diseases are characterized by protein aggregation and overlapping pathologies, challenging traditional classifications and highlighting shared underlying mechanisms. Parkinson’s disease and related synucleinopathies, including Lewy body dementia and multiple system atrophy, highlight the interplay between α-synuclein and tau, two key proteins implicated in these disorders. Recent studies reveal that tau and α-synuclein co-aggregate, interact synergistically, and propagate via prion-like mechanisms, exacerbating neuronal dysfunction. This review examines the physiological roles and pathological transitions of tau and α-synuclein, emphasizing their roles in microtubule dynamics, synaptic regulation, and the structural heterogeneity of aggregates. Evidence from post-mortem brains, transgenic models, and proteomic analyses underscores the significance of soluble oligomers as primary neurotoxic species and explores the diverse molecular composition of Lewy bodies and glial cytoplasmic inclusions. The co-localization of tau and α-synuclein, influenced by genetic factors and post-translational modifications, offers insights into shared mechanisms across synucleinopathies and tauopathies. These findings advocate for integrated therapeutic strategies targeting protein cross-seeding and proteostatic disruption while preserving physiological roles. By framing neurodegeneration as a collapse of proteostatic networks rather than isolated proteinopathies, this work proposes a paradigm shift toward understanding and treating complex neurodegenerative disorders.
What this study adds
Evidence grade: Low
This review describes how tau and alpha-synuclein co-aggregate and interact, and argues for integrated therapies targeting protein cross-seeding. It is a review of mechanisms and does not report any treatment that has been shown to work in patients.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Padilla-Godínez, F. J., Vázquez-García, E. R., Trujillo-Villagrán, M. I., Soto-Rojas, L. O., Palomero‐Rivero, M., Hernández‐González, O., et al. (2025). α-synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2025.1570553
Vancouver
Padilla-Godínez FJ, Vázquez-García ER, Trujillo-Villagrán MI, Soto-Rojas LO, Palomero‐Rivero M, Hernández‐González O, et al. α-synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies. Frontiers in Neuroscience. 2025. doi:10.3389/fnins.2025.1570553. PMID: 40212715.
BibTeX
@article{padillagodinez2025-40212715,
author = {Padilla-Godínez, Francisco Javier and Vázquez-García, Eunice Ruth and Trujillo-Villagrán, María Isabel and Soto-Rojas, Luis Oskar and Palomero‐Rivero, Marcela and Hernández‐González, Omar and Pérez-Eugenio, Francisco and Collazo-Navarrete, Omar and others},
title = {{α-synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies}},
journal = {Frontiers in Neuroscience},
year = {2025},
doi = {10.3389/fnins.2025.1570553},
pmid = {40212715},
url = {https://doi.org/10.3389/fnins.2025.1570553}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- These findings advocate for integrated therapeutic strategies targeting protein cross-seeding and proteostatic disruption while preserving physiological roles.
Why it matters
This review describes how tau and alpha-synuclein co-aggregate and interact, and argues for integrated therapies targeting protein cross-seeding. It is a review of mechanisms and does not report any treatment that has been shown to work in patients.
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in Neuroscience) |
| Journal's citation record | 2 / 4 | Frontiers in Neuroscience: journal h-index 226 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 36 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 12.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 5 / 6 | Cited 20.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 36 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Magdalena Guerra‐Crespo: h-index 16 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Universidad Nacional Autónoma de México: institution h-index 668 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40212715) |
| Free to read | 2 / 2 | Free to read |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fnins.2025.1570553
- PubMed: 40212715
- Original source →
- Free full text: Frontiers in Neuroscience →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 39.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Disease mechanisms from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.